MONROVIA, Calif., Aug. 7, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2017 and provided a review of business and clinical highlights.
“In the second quarter, we continued to advance our pipeline of wholly-owned and partnered XmAb® antibody drug candidates,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.
